Monoclonal antibodies (mAbs) are the fastest growing class of biopharmaceuticals reflecting their diverse applications in research and the clinic. The correct glycosylation of mAbs is required to elicit effector functions such as complement-dependent and antibody-dependent cell-mediated cytotoxicity, although these may be undesirable for the treatment of certain chronic diseases. To gain insight into the properties of glycan-deficient mAbs, we generated and characterized six different aglycosylated human IgG1 mAbs (carrying the N297A mutation) and compared them to their glycosylated counterparts. We found no differences in solubility or heterogeneity, and all mAbs the remained stable in stress tests at 4 and 37 °C. Surface plasmon resonance spectroscopy showed no differences in binding affinity, and the in vivo terminal serum half-life and plasma clearance were similar in rats. However, differential scanning calorimetry revealed that the aglycosylated mAbs contained a less stable C(H)2 domain and they were also significantly more susceptible to pH-induced aggregation. We conclude that aglycosylated mAbs are functionally equivalent to their glycosylated counterparts and could be particularly suitable for certain therapeutic applications, such as the treatment of chronic diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12033-012-9531-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adaptation of Aglycosylated Monoclonal Antibodies for Improved Production in Komagataella phaffii.
Biotechnol Bioeng
November 2024
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Monoclonal antibodies (mAbs) are a major class of biopharmaceuticals manufactured by well-established processes using Chinese Hamster Ovary (CHO) cells. Next-generation biomanufacturing using alternative hosts like Komagataella phaffii could improve the accessibility of these medicines, address broad societal goals for sustainability, and offer financial advantages for accelerated development of new products. Antibodies produced by K.
View Article and Find Full Text PDFExploring the Interplay Between Radioimmunoconjugates and Fcγ Receptors in Genetically Engineered Mouse Models of Cancer.
ACS Pharmacol Transl Sci
November 2024
Department of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.
Fcγ receptors (FcγR) are responsible for many of the interactions between immunoglobulins (IgG) and immune cells. In biomedicine, this interplay is critical to the activity of several types of immunotherapeutics; however, relatively little is known about how FcγRs affect the in vivo performance of radiolabeled antibodies. A handful of recent preclinical studies suggest that binding by FcγR-and particularly FcγRI-can affect the pharmacokinetic profiles of Zr-labeled radioimmunoconjugates, but there are no extant studies in immunocompetent or genetically engineered mouse models of cancer.
View Article and Find Full Text PDFevaluation of the role of Fab glycosylation in cetuximab antibody dynamics.
Front Immunol
August 2024
Analytical Excellence and Program Management, Merck Serono S.p.A., Rome, Italy.
Introduction: N-glycosylation is a post-translational modification that is highly important for the development of monoclonal antibodies (mAbs), as it regulates their biological activity, particularly in terms of immune effector functions. While typically added at the Fc level, approximately 15-25% of circulating antibodies exhibit glycosylation in the Fab domains as well. To the best of our knowledge, cetuximab (Erbitux) is the only therapeutic antibody presenting Fab glycosylation approved world-wide targeting the epidermal growth factor receptor for the treatment of metastatic-colorectal and head and neck cancers.
View Article and Find Full Text PDFModulation of the high concentration viscosity of IgG antibodies using clinically validated Fc mutations.
MAbs
July 2024
Department of Antibody Engineering, Genentech, Inc, South San Francisco, CA, USA.
Article Synopsis
- The self-association of therapeutic antibodies can lead to high viscosity, complicating manufacturing and limiting subcutaneous delivery, with previous solutions focusing on variable domain mutations and excipients.
- This study examined various Fc mutations on the viscosity of two IgG antibodies: omalizumab (anti-IgE) and trastuzumab (anti-HER2), revealing that certain Fc modifications significantly reduced omalizumab's high viscosity (from 176 cP).
- Molecular dynamics simulations provided insights into how these Fc mutations affect the antibodies' electrostatic and hydrophobic properties, suggesting that optimizing Fc mutations could improve future antibody therapies for easier subcutaneous administration.
Development of a first-in-class antibody and a specific assay for α-1,6-fucosylated prostate-specific antigen.
Sci Rep
July 2024
Roche Diagnostics GmbH, Nonnenwald, Penzberg, Germany.
Prostate-specific antigen (PSA) levels are widely used to screen for prostate cancer, yet the test has poor sensitivity, specificity and predictive value, which leads to overdiagnosis and overtreatment. Alterations in the glycosylation status of PSA, including fucosylation, may offer scope for an improved biomarker. We sought to generate a monoclonal antibody (mAb) targeting α-1,6-fucosylated PSA (fuc-PSA) and to develop a tissue-based immunological assay for fuc-PSA detection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!